Tubulis

Tubulis, founded in 2019, is a pharmaceutical company specializing in the development of protein-drug conjugates. The firm focuses on advancing antibody-drug conjugates (ADCs) by utilizing proprietary technologies to enhance design flexibility and therapeutic efficacy. By addressing critical challenges such as toxicity and indication constraints, Tubulis aims to redefine oncology treatments. The company operates at the intersection of biotechnology and clinical research, striving to deliver improved patient outcomes through innovative biologic insights and strategic industry collaborations.

The organization maintains a robust operational footprint with 2 locations and a workforce of 1,000-5,000 employees. This scale supports their extensive research and development pipeline, which is driven by a multidisciplinary team of scientists, doctors, and engineers. Meet Tubulis's team to learn about the leadership and technical expertise driving their clinical programs. Their commitment to scientific excellence is reflected in their focus on overcoming traditional ADC limitations, ensuring that their therapeutic candidates meet rigorous safety and performance standards within the competitive global pharmaceutical landscape.

Tubulis has demonstrated significant financial growth, reporting annual revenue of $41.0M. The company has successfully secured substantial capital through multiple funding rounds, including a recent Series C round. These investments from prominent venture capital firms underscore market confidence in their ADC platform and long-term commercial potential. Explore financial highlights for detailed metrics regarding their funding history and capital structure. As they continue to expand their pipeline, Tubulis remains positioned as a key player in the evolving oncology market, leveraging both internal innovation and external partnerships to advance their therapeutic portfolio.